Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA).
AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214
- Details
- Category: AstraZeneca
AstraZeneca and Targacept, Inc., announced the enrolment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.
34 Teachers and Schools Across North America Receive $10,000 Amgen Award
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the 18th annual Amgen Award for Science Teaching Excellence.
New SIMPONI (Golimumab) Data Shows Sustained Efficacy in the Treatment of Rheumatoid Arthritis
- Details
- Category: Merck
Findings from an open-label, uncontrolled long-term extension of a Phase 3 registration trial demonstrated efficacy of SIMPONI in patients with moderately to severely active rheumatoid arthritis despite methotrexate therapy at two years.
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
- Details
- Category: Novartis
Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, and OncoMed Pharmaceuticals, Inc., announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.
More Pharma News ...
- Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix
- Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients
- Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
- Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL
- Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint
- FDA advisory committee recommends approval of Novartis investigational treatment FTY720
- GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix